1NCCN.Non-small-cell-cancer practice guidelines[EB/OL].Prac-tice Guideli-nes in Oncology v2,2006.
2Namba Y,Kijima T,Yokota S,et al.Gefitinib in patients with brain metastases from non-small-cell lung cancer:review of 15 clinical cases[J].Clin Lung Cancer,2004,6(2):123-128.
3Ceresoli G L,Cappuzzo F,Gregorc V,et al.Gefitinib in patients with brain meta-stases from non-small-cell lung cancer:a prospective trial[J].Ann Oncol,2004,5(7):1042-1047.
4Hotta K,Kiuya K,Ueoka H,et al.Effect of gefitinib (Iressa,ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer[J].Lung Cancer,2004,46(2):255-261.
5Herbst R S,Prager D,Hermawn R,et al.Tribute:a phase Ⅲ trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer[J].J Clin Oncol,2005,23(25):5892-5899.
6Paez J G,Janne P A,Lee J C,et al.EGFR mutations in lung cancer:correla-tion with clinical response to gefitinib therapy[J].Science,2004,304(5676):1497-1500.
7Pao W,Miller V,Zakowski M,et al.EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib[J].Proc Natl Acad Sci USA,2004,101(36):13306-13311.
8Lynch T J,Bell D W,Soldella R,et al.Activating mutations in the epidermal grow-th factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib[J].N Engl J Med,2004,350(21):2129-2139.
9Kosaka T,Yatabe Y,Endon H,et al.Mutations of the epidermal growth factor receptor gene in lung cancer[J].Cancer Res,2004,64(24):8919-8923.
10Huang S F,Liu H P,Li L H,et al.High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan[J].Clin Cancer Res,2004,10(24):8195-8203.
